NasdaqGS:INGN

Stock Analysis Report

Executive Summary

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Inogen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.3%

INGN

-1.6%

US Medical Equipment

0.07%

US Market


1 Year Return

-72.8%

INGN

13.8%

US Medical Equipment

8.9%

US Market

Return vs Industry: INGN underperformed the US Medical Equipment industry which returned 13.8% over the past year.

Return vs Market: INGN underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

INGNIndustryMarket
7 Day5.3%-1.6%0.07%
30 Day8.5%-4.3%-0.3%
90 Day-15.2%-4.3%-1.6%
1 Year-72.8%-72.8%14.7%13.8%11.3%8.9%
3 Year0.6%0.6%70.7%65.6%46.3%36.8%
5 Year117.8%117.8%117.3%93.5%62.1%44.3%

Price Volatility Vs. Market

How volatile is Inogen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inogen undervalued compared to its fair value and its price relative to the market?

6.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: INGN ($52.01) is trading below our estimate of fair value ($55.38)

Significantly Below Fair Value: INGN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: INGN is good value based on its PE Ratio (26.8x) compared to the Medical Equipment industry average (41.8x).

PE vs Market: INGN is poor value based on its PE Ratio (26.8x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: INGN is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: INGN is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Inogen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

14.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INGN's forecast earnings growth (14.8% per year) is above the savings rate (2.7%).

Earnings vs Market: INGN's earnings (14.8% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: INGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: INGN's revenue (9.2% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: INGN's revenue (9.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Inogen performed over the past 5 years?

40.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: INGN's earnings have grown significantly by 40.6% per year over the past 5 years.

Accelerating Growth: INGN's earnings growth over the past year (30.7%) is below its 5-year average (40.6% per year).

Earnings vs Industry: INGN earnings growth over the past year (30.7%) exceeded the Medical Equipment industry 28.2%.


Return on Equity

High ROE: INGN's Return on Equity (12.6%) is considered low.


Return on Assets

ROA vs Industry: INGN has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: INGN's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Inogen's financial position?


Financial Position Analysis

Short Term Liabilities: INGN's short term assets ($340.7M) exceeds its short term liabilities ($46.4M)

Long Term Liabilities: INGN's short term assets (340.7M) exceeds its long term liabilities (23.6M)


Debt to Equity History and Analysis

Debt Level: INGN is debt free.

Reducing Debt: INGN has no debt compared to 5 years ago when its debt to equity ratio was 12%.

Debt Coverage: INGN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: INGN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: INGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if INGN's debt is covered by short term assets.


Next Steps

Dividend

What is Inogen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate INGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate INGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if INGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Inogen's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Scott Wilkinson (54yo)

2.6yrs

Tenure

US$2,687,338

Compensation

Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc.  ...


CEO Compensation Analysis

Compensation vs. Market: Scott's total compensation ($USD2.69M) is about average for companies of similar size in the US market ($USD2.67M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.8yrs

Average Tenure

40yo

Average Age

Experienced Management: INGN's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

5.2yrs

Average Tenure

59yo

Average Age

Experienced Board: INGN's board of directors are considered experienced (5.2 years average tenure).


Insider Trading

Insider Buying: INGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$42,93105 Sep 19
Loren McFarland
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$42.93
BuyUS$86,02020 Aug 19
Heath Lukatch
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares2,000
Max PriceUS$43.01

Ownership Breakdown


Management Team

  • Brenton Taylor (38yo)

    Co-founder & Executive VP of Engineering

    • Tenure: 18.8yrs
    • Compensation: US$929.83k
  • Ali Bauerlein (38yo)

    Co-founder

    • Tenure: 18.8yrs
    • Compensation: US$1.24m
  • Byron Myers (40yo)

    Executive Vice President of Sales & Marketing

    • Tenure: 2.8yrs
    • Compensation: US$928.61k
  • Scott Wilkinson (54yo)

    CEO, President & Director

    • Tenure: 2.6yrs
    • Compensation: US$2.69m
  • Bart Sanford (53yo)

    Executive Vice President of Operations

    • Tenure: 1.1yrs
    • Compensation: US$1.15m
  • Matt Bacso

    Investor Relations & Corporate Development Manager

    • Tenure: 0yrs

Board Members

  • R. Greer (61yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$240.74k
  • Heath Lukatch (52yo)

    Independent Chairman of the Board

    • Tenure: 11.8yrs
    • Compensation: US$296.24k
  • Richard Casaburi

    Member of Advisory Board

    • Tenure: 0yrs
  • Jeffrey Kupperman

    Member of Advisory Board

    • Tenure: 0yrs
  • Paul Selecky

    Member of Advisory Board

    • Tenure: 0yrs
  • Neil MacIntyre

    Member of Advisory Board

    • Tenure: 0yrs
  • Loren McFarland (60yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$236.24k
  • Scott Wilkinson (54yo)

    CEO, President & Director

    • Tenure: 2.6yrs
    • Compensation: US$2.69m
  • Robert Chatburn

    Member of Advisory Board

    • Tenure: 0yrs
  • Heather Rider (59yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$240.24k

Company Information

Inogen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inogen, Inc.
  • Ticker: INGN
  • Exchange: NasdaqGS
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.141b
  • Shares outstanding: 21.93m
  • Website: https://www.inogen.com

Number of Employees


Location

  • Inogen, Inc.
  • 326 Bollay Drive
  • Goleta
  • California
  • 93117
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2014
6IODB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United S ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/24 00:18
End of Day Share Price2019/10/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.